Status:
TERMINATED
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
Lead Sponsor:
Pfizer
Conditions:
Age Related Macular Degeneration (AMD)
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compare...
Detailed Description
A decision was made by the sponsor (08 May 2009) to terminate this study early; the study had achieved the primary objective prior to termination. This study was not terminated due to safety reasons.
Eligibility Criteria
Inclusion
- Evidence of neovascular AMD in at least one eye. In subjects with bilateral neovascular AMD, only one eye would be eligible for enrollment
- Baseline visual acuity of greater than or equal to 20/320, or better than 25 ETDRS letters in the study eye
Exclusion
- Previous treatment for CNV secondary to AMD, including any prior PDT with verteporfin, thermal laser photocoagulation, external beam radiation or transpupillary thermotherapy to the study eye
- Subjects having subfoveal fibrosis/ scar or atrophy representing \> 25% of the total lesion size
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT00327470
Start Date
July 1 2006
End Date
August 1 2009
Last Update
April 4 2012
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Graz, Austria, A-8036
2
Pfizer Investigational Site
Innsbruck, Austria, A-6020
3
Pfizer Investigational Site
Vienna, Austria, A-1030
4
Pfizer Investigational Site
Vienna, Austria, A-1180